Abstract
•
A comprehensive evaluation method for anti-SARS-CoV-2 drugs was established based on qPCR, TCID 50 , and immunofluorescence. •
A significant antiviral effect of rHuIFN-α1b was shown in Vero and Calu-3 cells. •
rHuIFN-α1b has a good potential in the application of anti-COVID-19 therapy.
All Keywords
【초록키워드】 therapy, drug, anti-SARS-CoV-2, Antiviral effect, qPCR, immunofluorescence, Calu-3, Vero, comprehensive evaluation, TCID, shown, 【제목키워드】 SARS-CoV-2, in vitro, recombinant, inhibit,
【초록키워드】 therapy, drug, anti-SARS-CoV-2, Antiviral effect, qPCR, immunofluorescence, Calu-3, Vero, comprehensive evaluation, TCID, shown, 【제목키워드】 SARS-CoV-2, in vitro, recombinant, inhibit,
{{{ 추상적인 }}}
•
qPCR, TCID 50 및 면역형광을 기반으로 anti-SARS-CoV-2 약물에 대한 포괄적인 평가 방법이 확립되었습니다. •
rHuIFN-α1b의 상당한 항바이러스 효과는 Vero 및 Calu-3 세포에서 나타났습니다. •
rHuIFN-α1b는 항-COVID-19 요법의 적용에서 좋은 잠재력을 가지고 있습니다.